Major HRT supplier sanctioned after whistleblowers raise concerns over patient safety
A group of employees from Theramex, which supplies HRT treatments to millions of patients in the UK, wrote a letter to the pharmaceutical regulator Association of the British Pharmaceutical Industry over allegations the company was not following regulatory standards and may 'jeopardise' patient safety.
The whistleblowers claimed some products featured inaccurate prescribing information and failed to highlight common side effects. They claimed they had been forced to contact the regulator after their attempts to raise issues internally were brushed off.
The company has now admitted it breached regulatory codes, amounting to 'bringing discredit upon, and reducing confidence in the pharmaceutical industry', according to an interim case report from the ABPI. It also failed to maintain high standards and provide accurate and up-to-date prescribing information, the report said.
Theramex is a global pharmaceutical company specialising in women's health products, such as hormone replacement therapy (HRT) and fertility treatments. Theramex UK is its London-based arm.
It supplies common HRT therapies including Evorel, Bijuve and Intrarosa. From April to June 2025, there were 760,000 prescriptions of Evorel and 2,748 prescriptions of Bijuve, according to data from the NHS Business Services Authority. In 2023-24, there were 2.8 million prescriptions of Evorel.
One employee wrote the complaint on behalf of a group, according to the complaint published by the Prescription Medicines Code of Practice Authority, which is part of the ABPI.
The complaint, filed in October 2024, said: 'We are a group of employees from various cross-functional teams at Theramex, and we are writing to express our growing concerns regarding the company's adherence to regulatory standards and the accountability of its leadership.
'While we have attempted to escalate these issues internally on numerous occasions, there has been a consistent lack of action or meaningful response, which leaves us with no choice but to seek external guidance and support.'
The complaint alleged that some of Theramex's products, such as Intrarosa and Evorel, had not had their prescribing information updated. In the case of Evorel, information for health professionals was 'incomplete' and did not include information on common side effects such as uterine spasms and vaginal infection, the letter claimed.
For another drug, the letter alleged that prescribing information had not been updated for five years.
The complaint warned: 'This oversight can lead to healthcare professionals (HCPs) not being fully informed of potential risks, which could jeopardise patient safety.'
The PMCPA panel found Theramix's 'failure to provide accurate and complete prescribing information was unacceptable'.
The employees also alleged the company failed to comply with regulators for clinical trial compliance warning. 'The lack of resources within Theramex's global headquarters to ensure compliance with these standards is alarming,' it said.
Finally, the letter alleged the company has a 'blame culture' that was 'deeply concerning.'
In response to the complaint, Theramex UK said it took its obligations under the ABPI code of practice 'very seriously' and launched an internal investigation.
It said that, although it had a process to update prescribing information, this was not sufficiently robust to ensure prescribing information was immediately updated.
The pharma company acknowledged it did not meet standards concerning this allegation and admitted that, at the time of the complaint, it did not have a process in place for clinical studies.
The employees' letter claimed it had tried to escalate matters to senior leaders within Theramex. The company claimed it was not aware of any of the matters having been escalated internally prior to them being reported to the regulator.
As part of the sanction, Theramex must provide written confirmation that it will cease practices that breach codes, pay a charge and advertise details of the case.
Theramex UK said it 'absolutely acknowledges' the recent ruling and 'respects the [regulator's] decision'. 'Of course, we remain fully committed to ensuring our practices align with the highest ethical standards and necessary steps and corrective measures have been taken,' it said.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Brains Aged Faster In 2021–2022: What Did The Pandemic Do To Us?
A new study suggests that the pandemic may have had a significant impact on our brains, whether or not we contracted COVID-19. Leveraging an extensive database of brain scans, British researchers say that people's brains showed accelerated aging during 2021 and 2022, including signs of shrinkage. While people who were infected with COVID also showed cognitive decline, like slower processing speed, the study was notable because it said even the non-infected were likely to experience harm to their brain. While the study did not delve into the exact causes of the accelerated aging, the study's first author, Ali-Reza Mohammadi-Nejad, a neuroimaging researcher at the University of Nottingham, theorizes that it may have been the result of stress and other factors. 'But it is likely that the cumulative experience of the pandemic—including psychological stress, social isolation, disruptions in daily life, reduced activity and wellness—contributed to the observed changes… In this sense, the pandemic period itself appears to have left a mark on our brains, even in the absence of infection,' said Mohammadi-Nejad, per NBC. The researchers found that males and 'those from more socioeconomically deprived backgrounds' experienced the most significant brain aging. Overall, the pandemic was thought to be linked to a 5.5-month acceleration in the aging process. This is not the first time researchers have reached similar conclusions. Last year, a previous study found that teenagers experienced dramatic brain aging during the pandemic. Notably, the study suggested that girls' brains aged 4.2 years faster and boys' brains aged 1.3 years faster, on average. The latest study does not indicate whether the structural changes identified in individuals who have never contracted COVID will result in any noticeable changes in brain function. Nor does the study confirm whether the physical changes will persist over the long term, says Adam Brickman, a professor of neuropsychology at Columbia University Vagelos College of Physicians and Surgeons, who was not involved in the study.
Yahoo
2 hours ago
- Yahoo
John Swinney pays tribute to Scottish woman who lost battle with anorexia aged 20
First Minister John Swinney has paid tribute to a young Scottish constituent who sadly lost her battle with anorexia earlier this year. The first minister attended a charity park run, which was organised by the family of Rachel Bywater from Aberfeldy, to raise funds for BEAT, the UK's leading charity supporting those affected by eating disorders, reports The Record. Swinney joined the family of Rachel, who sadly died on May 17 this year aged just 20 years old, at the event which has raised an amazing £7,500 for the charity. READ MORE: Netflix viewers rush to watch 'compelling' BBC drama series set in Edinburgh READ MORE: Edinburgh's first 'queer cafe' announces closure as owners say 'this is only the beginning' The MSP for Perthshire North shared a snap of the group together sporting their, 'Run for Rachel' t-shirts and wrote: "A special privilege to join the family of Rachel Bywater - one of my constituents who faced an eating disorder and sadly died recently aged only 20 - to run a 5k and raise funds for Beat (Eating Disorders). "Wonderful to see so many in the #Aberfeldy community supporting today." Her father Dave Bywater added: "Thank you John, it was great to have your support and that of the community. 'I hope everyone who reads these posts can realise there is a family behind this who are suffering a tragic loss, and ignore the offensive responses you have received." Join Edinburgh Live's Whatsapp Community here and get the latest news sent straight to your messages. Ahead of the event her family wrote: "We will be installing a new bench on the River Bank for Rachel Bywater, who very sadly passed away on May 17th this year. "To mark the occasion a fund raiser will be held on the Sunday to raise funds for BEAT (Eating Disorders). All you have to do is walk, jog or run 1, 2 or 3 laps of the FeldyRoo Fitness Trail. "The choice is yours, all we want is everyone to get involved. You can fill in an entry form and pick up sponsorship form at any of the pubs - Fountain, Black Wach or Schiehallion. "Entry is totally free but raised sponsorship or donations on the day would be really appreciated no matter how little or large."


Bloomberg
2 hours ago
- Bloomberg
Roche to Test Whether New Drug Can Prevent Alzheimer's Disease
Roche Holding AG plans to test whether an experimental medicine can prevent Alzheimer's disease symptoms in high-risk people, its latest investment in one of the most failure-prone areas of drugmaking. The new late-stage study will focus on people who are at risk of cognitive decline, Roche said in a statement late Sunday. The goal would be to slow down the emergence of symptoms, or prevent them entirely.